DxDiscovery, Inc.
DxDiscovery is a biotechnology Research & Development firm. The corporate goal is to develop quality, high-affinity antibodies to microbial antigens. These antibodies are incorporated into rapid POC diagnostics, or they may be developed as prophylactics/therapeutics for infectious disease. Our diagnostics portfolio includes products that will improve situations where current standard-of-care is time-consuming or has a high likelihood of producing an inaccurate result. The test platform is an immunoassay in which antibodies are used for biomarker detection. We discover the biomarkers and develop the antibodies that are central to assay construction.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Medical Research
- Market Focus:
- Nationally (across the country)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
DxDiscovery is a small business spinoff company located on the campus of the University of Nevada, Reno. We are academic in our origins and entrepreneurial in our culture. Research and development is funded by highly competitive grants from the National Institutes of Health and Department of Defense. Initially, DxDiscovery licenses technologies to partner companies who manufacture and distribute diagnostics. A long-term objective is in-house production of those products best suited for manufacture at the DxDiscovery site.
Our goal is to reduce the burden of disease in both developed and resource limited countries. Although the specific needs are very different in these two environments, many requirements for diagnostics are quite similar. Diagnostics should be affordable, give rapid results, and be usable at the point of patient care or need.
DxDiscovery will produce diagnostics that will be disruptive for improvement of patient care. Current diagnostics are reactive to patient symptoms. DxDiscovery will produce diagnostics that can be used early in the course of disease or for proactive screening before the onset of symptoms. Early diagnosis leads to more effective treatment.
Our approach is detection of biomarkers for disease – molecules that are produced by microbes, tumors or other conditions that are unique to the disease or condition. Familiar examples include the PSA test for prostate cancer, the “quick Strep” test for strep throat, or the home pregnancy test. The test platform is the immunoassay – use of antibodies to detect biomarkers.
We focus on diseases where alternative means for diagnosis such as culture or use of molecular probes is ineffective or not practical. In some cases, the biomarker is known and the challenge is production of antibodies that are used to detect the biomarker. In other cases, the biomarker is not known; in this instance, the process begins with target discovery.
Core technologies used in diagnostics discovery and development include molecular immunology, immunochemistry, monoclonal antibody production, and a target discovery strategy termed In vivo microbial antigen discovery (InMAD).
Overview
In many cases the antibodies developed for diagnostics purposes target surface expressed microbial antigens such as polysaccharides or proteins. Therefore, we are currently exploring the potential of antibodies for use as prophylaxis and/or therapy. Our therapeutics portfolio aims to introduce novel products into the marketplace that offer advantages over current standard-of-care. We focus on diseases where conventional treatment – such as antibiotics or supportive care – is ineffective, not practical, or does not meet the needs of a given situation; we are currently engaged in efforts to develop antibody-based medical countermeasures to the Tier 1 Select Agents B. pseudomallei and B. mallei for exactly this purpose.
DxDiscovery has a history of successful partnerships with investigators at the University of Nevada-Reno, University of South Alabama and Tulane University. These university partnerships contribute valuable expertise, facilities, and resources that greatly enhance the R&D capabilities of DxDiscovery.
